Academic Journal
Q1Drugs
About Drugs
Drugs is a scholarly journal published by its listed publisher. SCImago 2025 lists it in Q1, with an SJR of 3.5 and H-index of 212.
Coverage: 1971-2026. Research categories: Pharmacology (medical) (Q1).
Source-backed journal facts
Topics in published research
Antibiotics Pharmacokinetics and Efficacy; Blood Pressure and Hypertension Studies; Antibiotic Resistance in Bacteria; Asthma and respiratory diseases; Cancer Treatment and Pharmacology; Pneumonia and Respiratory Infections.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
5,990.00 USD; 4,690.00 EUR; 3,990.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Management of Multiple Sclerosis: Incorporating Recent Advances in Pathophysiology and Diagnosis to Guide Treatment Strategies
Moein Amin, Kaitlyn N. Palmer, Amjad Samara, Jeffrey A. Cohen et al.
2026-09-30 · DOI: 10.1007/s40265-026-02391-1GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks
Yahui Yuan, Chun Chen, Xiuming Li, Jingyi Guo et al.
2026-09-26 · DOI: 10.1007/s40265-026-02380-4Personalized Treatment of Hemophilia: Matching Therapies to Patient Needs in a Rapidly Evolving Landscape
Timea Szanto, Riitta Lassila
2026-09-25 · DOI: 10.1007/s40265-026-02386-yCamizestrant: First Approval
Arnold Lee
2026-09-25 · DOI: 10.1007/s40265-026-02385-zEfficacy and Safety of IGF-1 Receptor Inhibitors for Thyroid Eye Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials
Haiyang Zhang, Zixiang Zhang, Ting Lu, Sien Ping Chew et al.
2026-09-24 · DOI: 10.1007/s40265-026-02388-wPharmacotherapy of Irritable Bowel Syndrome with Constipation in Children: An Update on Clinical Progress and Successes
Maria Giovanna Puoti, Anna O. J. Oorthuys, Nicolaas Koen Vermeijden, Marc A. Benninga et al.
2026-09-23 · DOI: 10.1007/s40265-026-02376-0Vaccination for Gonorrhoea: Where Are We Now, and What Comes Next?
Valentin A. Slesarenko, Sharareh Eskandari, Evgeny A. Semchenko, Kate L. Seib et al.
2026-09-22 · DOI: 10.1007/s40265-026-02387-xAntibiotic-Refractory Chronic Pouchitis After Ileal Pouch-Anal Anastomosis: Current and Emerging Therapeutic Strategies
Ilaria Faggiani, Connor Tuttle, Silvio Danese, Laurent Peyrin-Biroulet et al.
2026-10 · DOI: 10.1007/s40265-026-02383-1Doravirine/Islatravir: First Approval
Sheridan M. Hoy
2026-09-12 · DOI: 10.1007/s40265-026-02367-1GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis
Charlotte Beaudart, Yveline Malréchauffé, Sophie van Heden, Dolores Sanchez-Rodriguez et al.
2026-10 · DOI: 10.1007/s40265-026-02365-3Current and Emerging Biomarkers and Surrogate Endpoints in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Mariam Alamgir, Aalam Sohal, Kris V. Kowdley
2026-10 · DOI: 10.1007/s40265-026-02369-zSafety Profile of the Non-steroidal Anti-inflammatory Drug Celecoxib in the Short-Term Management of Acute Non-cancer Pain: A Systematic Review with Meta-analysis of Randomised Controlled Trials
Carlos Mesa-Castrillon, Ye Tian, Jessica Hughes, Paula Beckenkamp et al.
2026-10 · DOI: 10.1007/s40265-026-02377-zAnbenitamab: First Approval
Hannah A. Blair
2026-09-12 · DOI: 10.1007/s40265-026-02382-2Atacicept: First Approval
Hannah A. Blair
2026-09-09 · DOI: 10.1007/s40265-026-02384-0Pivekimab Sunirine: First Approval
Yahiya Y. Syed
2026-09-04 · DOI: 10.1007/s40265-026-02378-yPlasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer’s Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes
John A. Hey, Susan Abushakra, Aidan Power, David Watson et al.
2026-10 · DOI: 10.1007/s40265-026-02381-3Vepdegestrant: First Approval
Simon Fung
2026-08-28 · DOI: 10.1007/s40265-026-02372-4Baxdrostat: First Approval
Hannah A. Blair
2026-10 · DOI: 10.1007/s40265-026-02373-3Non-invasive Assessment and Therapeutic Targeting in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Overcoming the Dissonance Between Drug Development and Precision Medicine
Eleni Theocharidou, Konstantinos Arvanitakis, Theocharis Koufakis, Emmanouil Tsochatzis et al.
2026-10 · DOI: 10.1007/s40265-026-02362-6Cefepime/Zidebactam: First Approval
Matt Shirley
2026-10 · DOI: 10.1007/s40265-026-02374-2Reviews
Community Reviews
Version History
September 13, 2026 at 2:15 am
September 13, 2026